The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

Lynparza approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer indication

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

China’s National Medical Products Administration granted AstraZeneca and Merck marketing authorization for Lynparza (olaparib) as a first-line maintenance treatment of adult patients with newly diagnosed advanced germline or somatic BRCA mutated (gBRCAm or sBRCAm) epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. The companies received marketing authorization Dec. 5.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more
By Kimlin Tam Ashing, Nadine J. Barrett, Kim F. Rhoads, Folakemi T. Odedina, Hayley S. Thompson and Camille C. R. Ragin
Table of Contents

Login

Looking for IP Login?